Discover Tesamorelin 10mg, a synthetic analog of human growth hormone-releasing hormone (GHRH / growth hormone-releasing factor). Marketed under the brand names Egrifta, Egrifta SV, and Egrifta WR, tesamorelin is the only FDA-approved medication specifically indicated for the reduction of excess abdominal (visceral) fat in HIV-infected adults with lipodystrophy.
This 44-amino-acid peptide features a stabilizing hexenoyl modification at the N-terminus that enhances resistance to enzymatic degradation while preserving high affinity for the GHRH receptor. The 10mg vial strength is commonly supplied for research and multi-dose reconstitution protocols.
Key Benefits & Research Applications of Tesamorelin 10mg
• Clinically proven reduction of visceral adipose tissue (VAT) in HIV-associated lipodystrophy (approximately 15% reduction vs placebo in pivotal Phase 3 trials).
• Stimulates endogenous, pulsatile growth hormone release rather than providing exogenous GH.
• Associated improvements in lipid profiles (triglycerides, total cholesterol/HDL ratio) observed in clinical studies.
• Potential research interest in body composition, metabolic health, and GHRH-axis modulation.
• Weight-neutral overall effect focused on visceral rather than subcutaneous fat.
How Tesamorelin Works
Tesamorelin binds to growth hormone-releasing hormone receptors on pituitary somatotroph cells. This activates adenylate cyclase, raises intracellular cAMP, and triggers the synthesis and pulsatile release of endogenous growth hormone (GH). Elevated GH subsequently increases insulin-like growth factor-1 (IGF-1) production. The resulting lipolytic and metabolic effects preferentially target visceral fat stores.
Unlike continuous GH administration, tesamorelin preserves a more physiological pulsatile pattern of secretion.
Dosage & Administration Considerations
The FDA-approved daily subcutaneous dose is formulation-dependent (typically 1.4 mg for Egrifta SV or equivalent adjusted dosing for newer formulations such as Egrifta WR). Injection is administered into the abdomen, with site rotation recommended. The 10mg research vial allows flexible reconstitution for laboratory or clinician-guided protocols. Always follow current prescribing information and medical supervision.
Tesamorelin is not indicated for general weight-loss management or non-HIV lipodystrophy uses.
Common Side Effects & Safety Profile
Frequently reported effects include injection-site reactions (erythema, pruritus, pain), arthralgia, extremity pain, myalgia, peripheral edema, paresthesia, and hypoesthesia. Increases in IGF-1 levels are expected and should be monitored. Other possible effects include fluid retention, elevated blood glucose in some individuals, and rare hypersensitivity reactions. Long-term cardiovascular safety has not been fully established. Contraindications include active malignancy, disruption of the hypothalamic-pituitary axis, known hypersensitivity, and pregnancy.
Important Disclaimer: Tesamorelin is a prescription medication. Research-grade 10mg vials are intended for laboratory research or use under qualified medical supervision only. Not for self-administration without proper training and oversight. This product is not intended to diagnose, treat, cure, or prevent any disease outside its approved indication. Consult a licensed healthcare provider and review the full prescribing information before use. Individual results vary.
Support advanced GHRH-axis and body-composition research with high-purity Tesamorelin 10mg. Verify third-party testing and source from reputable suppliers for consistent quality.
Massimo –
Potent tesa, I slept like a baby and it tightened up my mid section getting rid of a lot of visceral fat. 5/5!